Coinfusion of Low-Dose GLP-1 and Glucagon in Man Results in a Reduction in Food Intake
The DOI matches its Crossref record; 47 of the 49 references it cites were found in a registry or an index.
Abstract
Obesity is a growing epidemic, and current medical therapies have proven inadequate. Endogenous satiety hormones provide an attractive target for the development of drugs that aim to cause effective weight loss with minimal side effects. Both glucagon and GLP-1 reduce appetite and cause weight loss. Additionally, glucagon increases energy expenditure. We hypothesized that the combination of both peptides, administered at doses that are individually subanorectic, would reduce appetite, while GLP-1 would protect against the hyperglycemic effect of glucagon. In this double-blind crossover study, subanorectic doses of each peptide alone, both peptides in combination, or placebo was infused into 13 human volunteers for 120 min. An ad libitum meal was provided after 90 min, and calorie intake determined. Resting energy expenditure was measured by indirect calorimetry at baseline and during infusion. Glucagon or GLP-1, given individually at subanorectic doses, did not significantly reduce food intake. Coinfusion at the same doses led to a significant reduction in food intake of 13%. Furthermore, the addition of GLP-1 protected against glucagon-induced hyperglycemia, and an increase in energy expenditure of 53 kcal/day was seen on coinfusion. These observations support the concept of GLP-1 and glucagon dual agonism as a possible treatment for obesity and diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In human proof-of-concept studies, co-administration of GLP-1 and glucagon revealed benefits over GLP-1 receptor agonists alone, including further reduction in food intake, increased energy expenditure, increased hepatic fatty acid oxidation, reduced hepatic lipid accumulation, and improved mitochondrial function, without compromising glycaemic control.145”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [145]
In the citing paper
“In human proof-of-concept studies, co-administration of GLP-1 and glucagon revealed benefits over GLP-1 receptor agonists alone, including further reduction in food intake, increased energy expenditure, increased hepatic fatty acid oxidation, reduced hepatic lipid accumulation, and improved mitochondrial function, without compromising glycaemic control.145”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [145]
In the citing paper
“In human proof-of-concept studies, co-administration of GLP-1 and glucagon revealed benefits over GLP-1 receptor agonists alone, including further reduction in food intake, increased energy expenditure, increased hepatic fatty acid oxidation, reduced hepatic lipid accumulation, and improved mitochondrial function, without compromising glycaemic control.145”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [145]
In the citing paper
“In human proof-of-concept studies, co-administration of GLP-1 and glucagon revealed benefits over GLP-1 receptor agonists alone, including further reduction in food intake, increased energy expenditure, increased hepatic fatty acid oxidation, reduced hepatic lipid accumulation, and improved mitochondrial function, without compromising glycaemic control.145”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [145]
In the citing paper
“In human proof-of-concept studies, co-administration of GLP-1 and glucagon revealed benefits over GLP-1 receptor agonists alone, including further reduction in food intake, increased energy expenditure, increased hepatic fatty acid oxidation, reduced hepatic lipid accumulation, and improved mitochondrial function, without compromising glycaemic control.145”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [145]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(2000) · PubMed · Cited by 13,173
Obesity : Preventing and managing the global epidemic
Akram, D. S., Astrup, A. V., Atinmo, T., Boissin, J.-L., Bray, G. A., Carroll, K. N., Chitson, P., Chen, C., Dietz, W. H., Hill, J. O., et al. (2000) · Research at the University of Copenhagen (University of Copenhagen) · Cited by 12,945
New methods for calculating metabolic rate with special reference to protein metabolism
Weir, J. B. D. V. (1949) · The Journal of Physiology · doi:10.1113/jphysiol.1949.sp004363 · Cited by 5,603
The thrifty phenotype hypothesis
Hales, C. N., & Barker, D. J. P. (2001) · British Medical Bulletin · doi:10.1093/bmb/60.1.5 · Cited by 2,738
Calculation of substrate oxidation rates in vivo from gaseous exchange.
Frayn, K. N. (1983) · Journal of Applied Physiology · doi:10.1152/jappl.1983.55.2.628 · Cited by 2,365
Changes in Energy Expenditure Resulting from Altered Body Weight
Leibel, R. L., Rosenbaum, M., & Hirsch, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321001 · Cited by 2,012
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Self-citationThe SCOFF questionnaire: Assessment of a new screening tool for eating disorders
Morgan, J. F., Reid, F., & Lacey, J. H. (1999) · BMJ · doi:10.1136/bmj.319.7223.1467 · Cited by 1,416
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 1×
“The postprandial nausea seen in this study may instead be accounted for by a delay in gastric emptying triggered by glucagon and GLP-1 (31,32).”
BackgroundZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 1×
“As a result, GLP-1 is capable of achieving a modest reduction in body weight (12).”
BackgroundVilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970 · cited 3×
“GLP-1 analogs produce only a small weight loss in diabetic subjects or obese patients (14).”
BackgroundA new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
Verdich, C., Flint, A., Gutzwiller, J.-P., Näslund, E., Beglinger, C., Hellström, P. M., Long, S. J., Morgan, L. M., Holst, J. J., & Astrup, A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.9.7877 · Cited by 600
Abbott, C. R., Monteiro, M., Small, C. J., Sajedi, A., Smith, K. L., Parkinson, J. R. C., Ghatei, M. A., & Bloom, S. R. (2005) · Brain Research · doi:10.1016/j.brainres.2005.03.011 · Cited by 599
Self-citationThorens, B., Porret, A., Bühler, L., Deng, S.-P., Morel, P., & Widmann, C. (1993) · Diabetes · doi:10.2337/diab.42.11.1678 · Cited by 558
Willms, B., Werner, J., Holst, J. J., Orskov, C., Creutzfeldt, W., & Nauck, M. A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550773 · Cited by 502
Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
Pocai, A., Carrington, P. E., Adams, J. R., Wright, M., Eiermann, G., Zhu, L., Du, X., Petrov, A., Lassman, M. E., Jiang, G., et al. (2009) · Diabetes · doi:10.2337/db09-0278 · Cited by 409
Flint, A., Raben, A., Ersbøll, A., Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801627 · Cited by 384 · cited 1×
“Appetite inhibition classically results in defense of body weight by a reduction of energy expenditure (7,8).”
BackgroundBaggio, L. L., Huang, Q., Brown, T. J., & Drucker, D. J. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.04.063 · Cited by 372
Peptide YY3–36 and Glucagon-Like Peptide-17–36 Inhibit Food Intake Additively
Neary, N. M., Small, C. J., Druce, M. R., Park, A. J., Ellis, S. M., Semjonous, N. M., Dakin, C. L., Filipsson, K., Wang, F., Kent, A. S., et al. (2005) · Endocrinology · doi:10.1210/en.2005-0237 · Cited by 371
Self-citationWynne, K., Park, A. J., Small, C. J., Meeran, K., Ghatei, M. A., Frost, G. S., & Bloom, S. R. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803344 · Cited by 363
Self-citationVerdich, C. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.9.4382 · Cited by 336
Meeran, K., O’Shea, D., Edwards, C. M. B., Turton, M. D., Heath, M. M., Gunn, I., Abusnana, S., Rossi, M., Small, C. J., Goldstone, A. P., et al. (1999) · Endocrinology · doi:10.1210/endo.140.1.6421 · Cited by 303 · cited 1×
“The hypothalamus expresses both glucagon and GLP-1 receptors (34,35), and intracerebroventricular glucagon and GLP-1 are both capable of reducing food intake (36,37), suggesting that peripheral glucagon and GLP-1 could exert a direct effect on the hypothalamus after crossing the incomplete blood-brain barrier at the m…”
BackgroundSelf-citationGLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans
Näslund, E., Bogefors, J., Skogar, S., Grybäck, P., Jacobsson, H., Holst, J. J., & Hellström, P. M. (1999) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1999.277.3.r910 · Cited by 284
Tan, T. M., Field, B. C. T., McCullough, K. A., Troke, R. C., Chambers, E. S., Salem, V., Gonzalez Maffe, J., Baynes, K. C. R., De Silva, A., Viardot, A., et al. (2013) · Diabetes · doi:10.2337/db12-0797 · Cited by 258
Self-citationMinireview: Glucagon in the Pathogenesis of Hypoglycemia and Hyperglycemia in Diabetes
Cryer, P. E. (2012) · Endocrinology · doi:10.1210/en.2011-1499 · Cited by 242 · cited 1×
“It promotes glycogenolysis and gluconeogenesis, as well as hepatic fatty acid b-oxidation and ketogenesis (1).”
BackgroundInterrelationship of Glucagon, Insulin and Glucose: The Insulinogenic Effect of Glucagon
Samols, E., Marri, G., & Marks, V. (1966) · Diabetes · doi:10.2337/diab.15.12.855 · Cited by 199
Relative quantitative analysis of glucagon receptor mRNA in rat tissues
Svoboda, M., Tastenoy, M., Vertongen, P., & Robberecht, P. (1994) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(94)90162-7 · Cited by 169
GHATEI, M. A., UTTENTHAL, L. O., CHRISTOFIDES, N. D., BRYANT, M. G., & BLOOM, S. R. (1983) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-57-3-488 · Cited by 164
Self-citationHyperglucagonemia increases resting metabolic rate in man during insulin deficiency
NAIR, K. S. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-64-5-896 · Cited by 141
Minireview: Glucagon in Stress and Energy Homeostasis
Jones, B. J., Tan, T., & Bloom, S. R. (2012) · Endocrinology · doi:10.1210/en.2011-1979 · Cited by 140
Self-citationLeong, K. S., Walker, A. B., Martin, I., Wile, D., Wilding, J., & MacFarlane, I. A. (2001) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2001.01169.x · Cited by 140
Hormonal control of substrate cycling in humans.
Miyoshi, H., Shulman, G. I., Peters, E. J., Wolfe, M. H., Elahi, D., & Wolfe, R. R. (1988) · Journal of Clinical Investigation · doi:10.1172/jci113487 · Cited by 139
Individual, but not simultaneous, glucagon and cholecystokinin infusions inhibit feeding in men
Geary, N., Kissileff, H. R., Pi-Sunyer, X., & Hinton, V. J. (1992) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1992.262.6.r975 · Cited by 134
Selective hepatic vagotomy blocks pancreatic glucagon's satiety effect
GEARY, N., & SMITH, G. (1983) · Physiology & Behavior · doi:10.1016/0031-9384(83)90207-x · Cited by 134 · cited 1×
“A second mechanism might be via activation of vagal afferents to the brainstem, as vagotomy attenuates the anorectic effect of glucagon and GLP-1 after peripheral administration (38,39).”
BackgroundThe effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans
Flint, A., Raben, A., Rehfeld, J. F., Holst, J. J., & Astrup, A. V. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801126 · Cited by 131
Identification of glucagon receptors in rat brain.
Hoosein, N. M., & Gurd, R. S. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.14.4368 · Cited by 109
Gregersen, N., Møller, B., Raben, A., Kristensen, S., Holm, L., Flint, A., & Astrup, A. (2011) · Food & Nutrition Research · doi:10.3402/fnr.v55i0.7028 · Cited by 84
Carrier solutions for low-level intravenous insulin infusion.
Kraegen, E. W., Lazarus, L., Meler, H., Campbell, L. V., & Chia, Y. O. (1975) · BMJ · doi:10.1136/bmj.3.5981.464 · Cited by 75
Glucagon in physiological concentrations stimulates brown fat thermogenesis in vivo
Billington, C. J., Briggs, J. E., Link, J. G., & Levine, A. S. (1991) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1991.261.2.r501 · Cited by 71
Schepp, W., Dehne, K., Riedel, T., Schmidtler, J., Schaffer, K., & Classen, M. (2009) · Digestion · doi:10.1159/000201367 · Cited by 56
Central administration of glucagon suppresses food intake in chicks
Honda, K., Kamisoyama, H., Saito, N., Kurose, Y., Sugahara, K., & Hasegawa, S. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.02.011 · Cited by 53
Molecular Forms of Glucagon-Like Immunoreactivity in Porcine Intestine and Pancreas*
Ghatei, M. A., UTTENTHAL, L. O., Bryant, M. G., Christofides, N. D., MOODY, A. J., & Bloom, S. R. (1983) · Endocrinology · doi:10.1210/endo-112-3-917 · Cited by 52
Self-citationGlucagon and Its Receptor in Various Tissues
Christophe, J. (2006) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb17471.x · Cited by 32
Comparison of the effects of glucagon and atropine sulfate on gastric emptying.
Chernish, S. M., Brunelle, R. L., Rosenak, B. D., & Ahmadzai, S. (1978) · PubMed · Cited by 22
Exenatide and feeding: Possible peripheral neuronal pathways
Hunt, J. V., Washington, M. C., & Sayegh, A. I. (2011) · Peptides · doi:10.1016/j.peptides.2011.12.009 · Cited by 12
van Strien (1986) · doi:10.1002/1098-108x(198602)5:2<295::aid-eat2260050209>3.0.co;2-t
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“Co-infusion of GLP-1 and glucagon to human subjects resulted in decreased food intake, likely secondary to GLP-1 action, and increased energy expenditure, suggested to be driven by glucagon action [783,785].”
BackgroundSelf-citationA Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
Sanyal, A. J., Bedossa, P., Fraessdorf, M., Neff, G. W., Lawitz, E., Bugianesi, E., Anstee, Q. M., Hussain, S. A., Newsome, P. N., Ratziu, V., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401755 · Cited by 528
Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs
Artasensi, A., Pedretti, A., Vistoli, G., & Fumagalli, L. (2020) · Molecules · doi:10.3390/molecules25081987 · Cited by 494
The New Biology and Pharmacology of Glucagon
Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419
“The preclinical results are beginning to be corroborated by observations in non-human primates (274, 588) and clinical studies, which show that co-infusion of GLP-1 and glucagon decreases food intake (96) while increasing energy expenditure (575).”
ResultSignaling pathways in obesity: mechanisms and therapeutic interventions
Wen, X., Zhang, B., Wu, B., Xiao, H., Li, Z., Li, R., Xu, X., & Li, T. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01149-x · Cited by 410
Metadata
- Authors
- Cegla, J., Troke, R. C., Jones, B., Tharakan, G., Kenkre, J., McCullough, K. A., Lim, C. T., Parvizi, N., Hussein, M., Chambers, E. S., Minnion, J., Cuenco, J., Ghatei, M. A., Meeran, K., Tan, T. M., & Bloom, S. R.
- Affiliations
- Imperial College London (GB)
- Corresponding author
- Bloom, Stephen R.
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2014-10-13
- Volume
- 63
- Issue
- 11
- Pages
- 3711-3720
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2115939390
- Cited by
- 159
- References
- 49
- Citations by year
- 2026: 9 · 2025: 13 · 2024: 19 · 2023: 14 · 2022: 10 · 2021: 15 · 2020: 13 · 2019: 12 · 2018: 16 · 2017: 11 · 2016: 9 · 2015: 17 · 2014: 1
- FWCI
- 6.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Wellcome Trust
- National Institute for Health and Care Research (ACF-2007-21-023, ACF-2010-21-012, ACF-2010-21-017)
- Imperial College Healthcare NHS Trust
- National Institutes of Health
- Medical Research Council (MR/J010936/1, MR/K02115X/1, MR/K023667/1, MR/J010731/1)
- Biotechnology and Biological Sciences Research Council
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- glucagon-like peptide-1, glucagon, dietary intake, appetite, obesity, weight loss, satiety hormones, energy expenditure, hyperglycemia, diabetes treatment
- MeSH terms
- Adult, Eating, Glucagon, Humans, Hyperglycemia, Male, Cross-Over Studies, Glucagon-Like Peptide 1, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.